<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333291</url>
  </required_header>
  <id_info>
    <org_study_id>2013/1497</org_study_id>
    <nct_id>NCT03333291</nct_id>
  </id_info>
  <brief_title>Fecal Transplantation in Patients With IBS</brief_title>
  <official_title>Characterisations of Microbial Community Composition and Kinetics Following Faecal Microbiota Transplantation in Patients WITH IRRITABLE BOWEL SYNDROME</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helse Vest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haukeland University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will characterize the biology of FMT in the context of IBS prior to wider clinical&#xD;
      application of the method. Given the ethical concerns of unknown and long-term adverse&#xD;
      effects of FMT therapy, the study will include patients only with moderate to severe&#xD;
      symptoms. IBS is a heterogenous disorder and it is important to characterize the patients,&#xD;
      and study as homogeneous patient populations as possible. Therefore the study will only&#xD;
      include post-infectious IBS patients after the Giardia outbreak.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary aims:&#xD;
&#xD;
      Detailed characterisation of donor and recipient microbial community composition (by means of&#xD;
      16S rRNA profiling) and determination of the kinetics of changes following FMT&#xD;
&#xD;
      Secondary aims:&#xD;
&#xD;
        -  Determination of interactions of importance to persisting recipient gut microbiota.&#xD;
&#xD;
        -  Evaluate safety of FMT in an IBS population&#xD;
&#xD;
        -  To evaluate the efficacy of FMT in relieving symptoms in selected patients with IBS in&#xD;
           an open pilot trial in order to have the possibility to calculate number of patients&#xD;
           needed when planning future controlled studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2016</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">June 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Stool microbiota changes</measure>
    <time_frame>up to 28 weeks</time_frame>
    <description>abundance of major microbial taxa in fecal transplant post transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global improvement in IBS symptoms</measure>
    <time_frame>up to 28 weeks</time_frame>
    <description>Patient questionnaires IBSS-S</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Fecal transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duodenal transfer of healthy donor fecal suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fecal suspension</intervention_name>
    <description>helathy donor fecal suspension administered by duodenal scope</description>
    <arm_group_label>Fecal transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-and 70 years&#xD;
&#xD;
          -  IBS-SSS (IBS-Symptom Severity Scale) score &gt;175 (175 - 300 represents moderate, &gt; 300&#xD;
             represent severe IBS).&#xD;
&#xD;
          -  All patients are required to have symptoms for at least 12 months, fulfilling the Rome&#xD;
             III criteria with either diarrhoea-predominant irritable bowel syndrome (IBS-D) or&#xD;
             alternating constipation and diarrhoea (IBS-A) with bloating or flatulence as&#xD;
             predominant symptoms. Only IBS considered post-infectious after the Bergen Giardia&#xD;
             outbreak will be included. The severity of global IBS symptoms has to be either&#xD;
             moderate (&quot;cannot be ignored but do not influence daily activities&quot;) or severe&#xD;
             (&quot;influence daily activities&quot;). A decrease of 50 points on the IBS-SSS has been shown&#xD;
             to correlate with improvement in clinical symptoms. All patients will undergo&#xD;
             appropriate investigations to exclude organic disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of inflammatory bowel diseases, gastrointestinal malignancy, blood in stool or&#xD;
             antibiotic use within 1 month prior to FMT, immunocompromised patient defined as&#xD;
             taking immuno-suppressive medications, history of opportunistic infections within 1&#xD;
             year prior to FMT, oral thrush, or disseminated lymphadenopathy.&#xD;
&#xD;
          -  Patients who are scheduled for abdominal surgery, pregnant women or patients taking&#xD;
             probiotics or taking antibiotics within 4 weeks prior to installation are also&#xD;
             excluded from the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helse Bergen HF, Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

